This Article Full Text (PDF) All Versions of this Article: 0962280208092346v1 18/1/53    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by 'Chris' Delaney, J. A Articles by Suissa, S. Search for Related Content PubMed PubMed Citation Articles by 'Chris' Delaney, J. A Articles by Suissa, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB WARFARIN Social Bookmarking                         What's this?

The case-crossover study design in pharmacoepidemiology

Department of Biostatistics, University of Washington, Seattle, Washington, United States

Samy Suissa

Division of Clinical Epidemiology, McGill University Health Center, Montreal, Canada and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada, samy.suissa{at}clinepi.mcgill.ca

In the study of the association of transient drug exposures with acute outcomes, the case-crossover design is an efficient alternative to the case-control approach. This design based exclusively on the case series uses within-subject comparisons of drug exposures over time to estimate the rate ratio of the outcome associated with the drug under study. This design inherently removes the biasing effects of unmeasured, time-invariant confounding factors from the estimated rate ratio, but is sensitive to several assumptions. We illustrated the case-crossover design and explored its sensitivity using data from 4028 cases of gastrointestinal bleeding from the General Practice Research Database in assessing the effects of the drug warfarin. We compared the use of different time window lengths to assess exposure and considered the use of a case-time-control design to account for exposure time trends. The case-crossover approach found no excess risk of bleeding with warfarin exposure [rate ratio 0.98; 95% confidence interval (CI): 0.74—1.28] using a 1-month time window. When we restricted the analysis to subjects with truly transient drug exposure, defined by 1 to 3 prescriptions in the previous year, the rate ratio was 2.59 (95% CI: 1.42—4.74). To consider the longer 1-year exposure time window, the case-time-control approach was used and resulted in a rate ratio of 1.72 (95% CI: 1.08—2.43). In conclusion, the case-crossover design is potentially a powerful approach to assess the risk of drugs. This design is, however, highly sensitive to assumptions about intermittency of drug use and the length of the exposure time window, as demonstrated with the example of bleeding associated with warfarin use.

This version was published on February 1, 2009

Statistical Methods in Medical Research, Vol. 18, No. 1, 53-65 (2009)
DOI: 10.1177/0962280208092346


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?